Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Clopidogrel, one of the most commonly prescribed medications, is a prodrug requiring CYP450 biotransformation. Data suggest its pharmacologic effect varies based on CYP2C19 genotype, but there is uncertainty regarding the clinical risk imparted by specific genotypes.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): JAMA

Title: JAMA

Publisher: American Medical Association (AMA)

ISSN (Electronic): 1538-3598

ISSN (Print): 0098-7484

Publication date (Electronic): Oct 27 2010

Volume: 304

Issue: 16

Affiliations

[1 ] TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA. jmega@partners.org

Article

Publisher Item ID: 304/16/1821 Mid ID: NIHMS268168

DOI: 10.1001/jama.2010.1543

PMC ID: 3048820

PubMed ID: 20978260

SO-VID: 1417cfd8-b924-47e8-919e-7dc743043c6f

History

Data availability:

Comments

Comment on this article

scite_

1,077

790

Smart Citations

1,077

790

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.